Evidence map›Paper›PMID 30575753›Full record

ArticleNature communications2018

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

James B Whitney, So-Yon Lim, Christa E Osuna, Jessica L Kublin, Elsa Chen, Gyeol Yoon, Po-Ting Liu, Peter Abbink, Erica N Borducci, Alison Hill and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Guideline
  2. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025
    Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Maintenance of intestinal CX3CR1Nature communications · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

James B WhitneyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. jwhitne2@bidmc.harvard.edu.
So-Yon LimCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-9654-2335
Christa E OsunaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0003-2761-2456
Jessica L KublinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Elsa ChenCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Gyeol YoonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Po-Ting LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-5931-064X
Peter AbbinkCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0003-1978-088X
Erica N BorducciCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Alison HillProgram for Evolutionary Dynamics, Harvard University, Cambridge, MA, 02138, USA.ORCID http://orcid.org/0000-0002-6583-3623
Mark G LewisBioqual, Rockville, MD, 20852, USA.
Romas GeleziunasGilead Sciences, Foster City, CA, 94404, USA.
Merlin L RobbU.S. Military HIV Research Program, Henry Jackson Foundation, 6720 Rockledge Drive, Bethesda, MD, 20817, USA.
Nelson L MichaelWalter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD, 20910, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. dbarouch@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USBioqual · USGilead Sciences (United States) · USHarvard University · USJackson Foundation · USWalter Reed Army Institute of Research · US

Funding

Consortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0M
Combined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6M
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2012 to 2016
$18.0M
Project 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2018 to 2022
$14.0M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Viral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5M
TLR Immunotherapy to Eradicate Anatomic SIV ReservoirsR01AI127089 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2016 to 2020
$3.5M
Mechanisms of SIV persistenceR56AI091514 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2011 to 2011
$849k
TLR Therapy to Eradicate the SIV ReservoirR56AI122942 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2016 to 2016
$738k
NIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI127089NIAID NIH HHS R56 AI091514NIAID NIH HHS R56 AI122942NIAID NIH HHS T32 AI007387NIAID NIH HHS U19 AI096040NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI126603
6 · The paper itself

Abstract

The precise time when the viral reservoir is seeded during acute HIV-1 infection remains unclear. We previously demonstrated that the viral reservoir was seeded by day 3 following SIVmac251 infection in rhesus monkeys. Here we report the impact of initiating ART on day 0 (6 h), 1, 2, or 3 following intrarectal SIVmac251 infection in 20 rhesus monkeys (N = 5/group). After 6 months of daily suppressive ART, antiretroviral drugs were discontinued, and viral rebound was monitored. 0% (0 of 5), 20% (1 of 5), 60% (3 of 5), and 100% (5 of 5) of animals that initiated ART on days 0 (6 h), 1, 2, or 3, respectively, showed viral rebound following ART discontinuation and correlated with integrated viral DNA in lymph node CD4+ T cells. These data demonstrate that the viral reservoir is seeded within the first few days of infection and that early ART initiation limits the viral reservoir.

Indexed as

AnimalsAnti-Retroviral AgentsCD4-Positive T-LymphocytesDrug Therapy, CombinationMacaca mulattaMaleModels, BiologicalSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnti-Retroviral Agents

Identifiers

PMID30575753
PMCPMC6303321
OpenAlexW2904106640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.